Review article: Gastro-oesophageal reflux disease - How wide is its span?

Alimentary Pharmacology and Therapeutics, Supplement

Volumn 20, Issue 5, 2004, Pages 27-37

  Talley, N J ^a,b  

^a Mayo Clinic   (United States)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOCARCINOMA; ADULT; AGED; ASIA; BARRETT ESOPHAGUS; CLINICAL PRACTICE; CONFERENCE PAPER; DIETARY INTAKE; ENDOSCOPY; ERADICATION THERAPY; ESOPHAGUS CARCINOMA; FEMALE; GASTROESOPHAGEAL REFLUX; HEARTBURN; HELICOBACTER PYLORI; HIGH RISK PATIENT; HUMAN; MALE; OBESITY; PREVALENCE; PRIORITY JOURNAL; REFLUX ESOPHAGITIS; STOMACH ACID SECRETION; SYMPTOMATOLOGY; WESTERN HEMISPHERE;

EID: 7044249043     PISSN: 09530673     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.02134.x     Document Type: Conference Paper

References (81)

1. Nebel OT, Fornes MF, Castell DO. Symptomatic gastroesophageal reflux: incidence and precipitating factors. Dig Dis Sci 1976; 21: 953-6.
2. Thompson WG, Heaton KW. Heartburn and globus in apparently healthy people. Can Med Assoc J 1982; 126: 46-8.
3. Locke GR 3rd, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ. Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota. Gastroenterology 1997; 112: 1448-56.
4. Lagergren J, Bergström R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med 1999; 340: 825-31.
5. Nandurkar S, Talley NJ. Epidemiology and natural history of reflux disease. Baillieres Best Pract Res Clin Gastroenterol 2000; 14: 743-57.
6. Fass R, Ofman JJ. Gastroesophageal reflux disease - should we adopt a new framework? Am J Gastroenterol 2002; 97: 1901-9.
7. Dent J, Brun J, Fendrick AM, et al. An evidence-based appraisal of reflux disease management - the Genval workshop report. Gut 1999; 44(Suppl, 2): S1-16.
8. Lundell LR, Dent J, Bennett JR, et al. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999; 45: 172-80.
9. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 1999; 94: 1434-42.
10. Graham DY, Smith JL, Patterson DJ. Why do apparently healthy people use antacid tablets? Am J Gastroenterol 1983; 78: 257-60.
11. DeVault KR, Castell DO. Current diagnosis and treatment of gastroesophageal reflux disease. Mayo Clin Proc 1994; 69: 867-76.
12. Katz, PO. Treatment of gastroesophageal reflux disease: use of algorithms to aid in management. Am J Gastroenterol 1999; 94(11 Suppl.): S3-10.
13. Johansson KE, Ask P, Boeryd B, Fransson SG, Tibbling L. Oesophagitis, signs of reflux andc acid secretion in patients with symptoms of gastro-oseophageal reflux disease. Scand J Gastroenterol 1986; 21: 137-47.
14. Venables T, Newland RD, Patel AC, Hole J, Wilcock C, Turbitt ML. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams, once daily or ranitidine 150 milligrams twice daily evaluated as initial therapy for the relief of symptoms of gastroesophageal reflux disease in general practice. Scand J Gastroenterol 1997; 32: 965-73.
15. Thomson AB, Barkun AN, Armstrong D, et al. The prevalence of clinically significant endoscopic findings in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment-prompt endoscopy (CADET-PE) study. Aliment Pharmacol Ther 2003, 17: 1481-91.
16. Ronkainen JA, Aro PT, Storskrubb T, et al. Prevalence of esophagitis and endoscopy-negative reflux disease in a population. A report from the Kalixanda study. Gastroenterology 2002; 122(Suppl.): A213(S1357).
17. Aro PT, Ronkainen JA, Storskrubb T. et al. Findings at upper endoscopy in a random adult population. A report from the Kalixanda study. Gastroenterology 2002; 122(Suppl.): A568(Abstract).
18. Lind T, Havelund T, Carlsson R, et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997; 32: 974-9.
19. Pandolfino JE, Richter JE, Ours T, Guardino JM, Chapman J, Kahrilas P. Ambulatory esophageal pH monitoring using a wireless system. Am J Gastroenterol 2003; 98: 740-9.
20. Shi G, Bruley des Varannes S, Scarpignato C, Le Rhun M, Galmiche JP. Reflux related symptoms in patients with normal oesophageal exposure to acid. Gut 1995; 37: 457-64.
21. Trimble KC, Pryde A, Heading RC. Lowered oesophageal sensory thresholds in patients with symptomatic but not excess gastro-oesophageal reflux: evidence for a spectrum of visceral sensitivity in GORD. Gut 1995; 37: 7-12.
22. Balaji NS, Blom D, DeMeester TR, Peters JH. Redefining gastroesophageal reflux (GER). Surg Endosc 2003; 17(9): 1380-5.
23. Castell DO, Vela M. Combined multichannel intraluminal impedance and pH-metry: an evolving technique to measure type and proximal extent of gastroesophageal reflux. Am J Med 2001; 111(Suppl. 8A): 157S-159S.
24. McDougall NI, Johnston BT, Kee F, Collins JS, McFarland RJ, Love AH. Natural history of reflux oesophagitis: a 10 year follow-up of its effect on patient symptomatology and quality of life. Gut 1996; 38: 481-6.
25. Goh KL, Chang CS, Fock KM, Ke M, Park HJ. Lam SK. Gastro-oesophageal reflux disease in Asia. J Gastroenterol Hepatol 2000; 15: 230-8.
26. Chang CS, Poon SK, Lien HC. Chen GH. The incidence of reflux esophagitis among the Chinese. Am J Gastroenterol 1997; 92: 668-71.
27. Yeh C. Hsu CT. Ho AS, Sampliner RE, Fass R. Erosive esophagitis and Barrett's esophagus in Taiwan: a higher frequency than expected. Dig Dis Sci 1997; 42: 702-6.
28. Ho KY, Lim LS, Goh WT, Lee JMJ. The prevalence of gastro-oesophageal reflux has increased in Asia: a longitudinal study in the community. J Gastroenterol Hepatol 2001; 16(Suppl.): A132(Abstract).
29. HO KY, Kang JY, Seow A. Prevalence of gastrointestinal symptoms in a multiracial Asian population, with particular reference to reflux-type symptoms. Am J Gastroenterol 1998; 93: 1816-22.
30. Wong WM, Lai KC, Lau CP, et al. Upper gastrointestinal evaluation of Chinese patients with non-cardiac chest pain. Aliment Pharmacol Ther. 2002; 16: 465-71.
31. Lagergren J, Ye W, Bergstrom R, Nyren O. Utility of endoscopic screening for upper gastrointestinal adenocarcinoma. J Am Med Assoc 2000; 284: 961-2.
32. Nilsson M, Johnsen R, Ye W, Hveen K, Lagergren J. Obesity and estrogen as risk factors for gastroesophageal reflux symptoms. J Am Med Assoc 2003; 290: 66-72.
33. Locke GR 3rd, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ 3rd. Risk factors associated with symptoms of gastroesophageal reflux. Am J Med 1999; 106: 642-9.
34. Lagergren J, Bergstrom R, Nyren O. Association between body mass and adenocarcinoma of the esophagus and gastric cardia. Ann Intern Med 1999; 130: 883-90.
35. Sonnenberg A. Temporal trends and geographical variations of peptic ulcer disease. Aliment Pharmacol Ther 1995; 9(Suppl. 2): 3-12.
36. El-Serag HB, Sonnenberg A. Opposing time trends of peptic ulcer and reflux disease. Gut 1998; 43: 327-33.
37. Blaser MJ. Polymorphic bacteria persisting in polymorphic hosts: assessing Helicobacter pylori-related risks for gastric cancer. J Natl Cancer Inst 2002; 94: 1662-3.
38. Laine L, Sugg J. Effect of Helicobacter pylori eradication on development of erosive esophagitis and gastroesophageal reflux disease symptoms: a post hoc analysis of eight double blind prospective studies. Am J Gastroenterol 2002; 97: 2992-7.
39. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345: 784-9.
40. Cameron AJ, Lagergren J, Henriksson C, Nyren O, Locke GR 3rd, Pedersen NL. Gastroesophageal reflux disease in monozygotic and dizygotic twins. Gastroenterology 2002; 122: 55-9.
41. Armstrong D. Endoscopic evaluation of gastroesophageal reflux disease. Yale J Biol Med 1999; 72(2-3): 93-100.
42. Bytzer P, Hansen JM, Schaffalitzky de Muckadell OB, Malchow-Moller A. Predicting endoscopic diagnosis in the dyspeptic patient. The value of predictive score models. Scand J Gastroenterol 1997; 32: 118-25.
43. Blustein PK, Beck PL, Meddings JB, et al. The utility of endoscopy in the management of patients with gastroesophageal reflux symptoms. Am J Gastroenterol 1998; 93: 2508-12.
44. Martinez SD, Malagon IB, Garewal HS, Gui H, Fass R. Non-erosive reflux disease (NERD) - acid reflux and symptom patterns. Aliment Pharmacol Ther 2003; 17: 537-45.
45. Knill-Jones RP, Card WI, Crean CP, James WB, Spiegelhalter DJ. The symptoms of gastro-oesophageal reflux and oesophagitis. Scand J Gastroenterol 1984; 19(Suppl. 106): 72-6.
46. Carlsson R, Dent J, Watts R, et al. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. Eur J Gastroenterol Hepatol 1998; 10: 119-24.
47. Locke GR, Zinsmeister AR, Talley NJ. Can symptoms predict endoscopic findings in GERD? GI Endoscopy 2003; 5(5): 661-70.
48. Isolauri J, Luostarinen M, Isolauri E, Reinikainen P, Viljakka M, Keyrilainen O. Natural course of gastroesophageal reflux disease: 17-22 year follow-up of 60 patients. Am J Gastroenterol 1997; 92: 37-41.
49. Manabe N, Yoshihara M, Sasaki A, Tanaka S, Haruma K, Chayama K. Clinical characteristics and natural history of patients with low-grade reflux esophagitis. J Gastroenterol Hepatol 2002; 17: 949-54.
50. Pace F, Santalucia F, Bianchi Porro G. Natural history of gastro-oesophageal reflux disease without oesophagitis. Gut 1991; 32: 845-8.
51. Armstrong D, Pare P, Pericak D, Pyzyk M, Canadian Pantoprazole GERD Study Group. Symptom relief in gastro-oesophageal reflux disease: a randomized, controlled comparison of pantoprazole and nizatidine in a mixed patient population with erosive oesophagitis or endoscopy-negative reflux disease. Am J Gastroenterol 2001; 96: 2849-57.
52. Armstrong D, Talley NJ, Lauritson K, et al. The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole. Aliment Pharmacol Ther 2004; 20.
53. Maton PN, Vakil NB, Hwang C, et al. The impact of baseline severity of erosive esophagitis (EE) on heartburn (HB) resolution in patients treated with esomeprazole or omeprazole. Gastroenterology 2001; 120(Suppl. 1): A435(Abstract).
54. Armstrong D, Vieth M, Fiocca R. Are endoscopy-negative GERD and reflux esophagitis different diseases? Baseline histology in GERD patients off-therapy - the CHEER Study. Gastroenterology 2003; 124(4 Suppl. 1): A416(Abstract).
55. Vieth M, Leodolter A, Kulig M, et al. The effects of esomeprazole on the oesophageal epithelium. Gut 2002; 51(Suppl. III): Al 70(Abstract).
56. Solcia E, Villani L, Luinetti O, et al. Altered intracellular glycoconjugates and dilated intercellular spaces of esophageal epithelium in reflux disease. Virchows Arch 2000; 436: 207-16.
57. Spechler SJ. Epidemiology and natural history of gastro-oesophageal reflux disease. Digestion 1992; 51(Suppl. 1): 24-9.
58. Cameron AJ, Arora AS. Barrett's esophagus and reflux esophagitis: is there a missing link? Am J Gastroenterol 2002; 97: 273-8.
59. Spechler SJ, Goyal RK. Barrett's esophagus. N Engl J Med 1986; 315: 362-71.
60. Blot WJ, Devesa SS, Kneller R, Fraumeni FR Jr. Rising incidence of adenocarcinoma of the esophagus and gastric cardia. J Am Med Assoc 1991; 265: 1287-9.
61. Ye W, Chow WH, Lagergren J, Yin L. Nyren O. Risk of adenocarinomas of the esophagus and gastric cardia in patients with gastroesophageal reflux diseases and after antireflux surgery. Gastroenterology 2001; 121: 1286-93.
62. Richter JE, Bradley LA, Castell DO. Esophageal chest pain: current controversies in pathogenesis, diagnosis and therapy. Ann Intern Med 1989; 110: 66-78.
63. Eslick GD, Jones MP, Talley NJ. Non-cardiac chest pain: prevalence, risk factors, impact and consulting - a population-based study. Aliment Pharmacol Ther 2003; 17: 1115-24.
64. Davies HA, Jones DB, Rhodes J, Newcombe RG. Angina-like esophageal pain: differentiation from cardiac pain by history. J Clin Gastroenterol 1985; 7: 477-81.
65. Fass R, Fennerty MB, Ofman JJ, et al. The clinical and economic value of a short course of omeprazole in patients with noncardiac chest pain. Gastroenterology 1998; 115: 42-9.
66. Achem SR, Kolts BE, MacMath T, et al. Effects of omeprazole versus placebo in treatment of noncardiac chest pain and gastroesophageal reflux. Dig Dis Sci 1997; 42: 2138-45.
67. Stahl WG, Beton RR, Johnson CS, Brown CL, Waring JP. Diagnosis and treatment of patients with gastroesophageal reflux and noncardiac chest pain. South Med J 1994; 87: 739-42.
68. Pandak WM, Arezo S, Everett S, et al. Short course of omeprazole: a better first diagnostic approach to noncardiac chest pain than endoscopy, manometry, or 24-hour esophageal pH monitoring. J Clin Gastroenterol 2002; 35: 307-14.
69. Xia HHX, Lai KC, Lam SK, et al. Symptomatic response to lansoprazole predicts abnormal acid reflux in endoscopy-negative patients with non-cardiac chest pain. Aliment Pharmacol Ther 2003; 17: 369-77.
70. Wu DN, Tanifuji Y, Kobayashi H, et al. Effects of esophageal acid perfusion on airway hyperresponsiveness in patients with bronchial asthma. Chest 2000; 118: 1553-6.
71. Peters FT, Kleibeuker JH, Postma DS. Gastric asthma: a pathophysiological entity? Scand J Gastroenterol 1998; 225(Suppl.): 19-23.
72. D'Urzo A, Jugovic P. Chronic cough. Three most common causes. Can Fam Physician 2002; 48: 1311-6.
73. Jailwala JA, Shaker R. Oral and pharyngeal complications of gastroesophageal reflux disease. Globus, dental erosions, and chronic sinusitis. J Clin Gastroenterol 2000; 30(3 Suppl.): S35-8.
74. Ing AJ. Interstitial lung disease and gastroesophageal reflux. Am J Med 2001; 111(Suppl. 8A): 41S-44S.
75. Close LG. Laryngopharyngeal manifestations of reflux: diagnosis and therapy. Eur J Gastroenterol Hepatol 2002; 14(Suppl. 1): S23-7.
76. Harding SM. Acid reflux and asthma. Curr Opin Pulm Med 2003; 9: 42-5.
77. Zerbib F, Guisset O, Lamouliatte H, Quinton A, Galmiche JP, Tunon-De-Lara JM. Effects of bronchial obstruction on lower esophageal sphincter motility and gastroesophageal reflux in patients with asthma. Am J Respir Crit Care Med 2002; 166: 1206-11.
78. Ye W, Chow WH, Lagergren J, et al. Risk of adenocarcinomas of the oesophagus and gastric cardia in patients hospitalized for asthma. Br J Cancer 2001; 85: 1317-21.
79. Paterson WG. Extraesophageal manifestations of reflux disease: myths and reality. Chest Surg Clin N Am 2001; 11: 523-38.
80. El-Serag HB, Lee P, Buchner A, Inadomi JM, Gavin M, McCarthy DM. Lansoprazole treatment of patients with chronic idiopathic laryngitis: a placebo-controlled trial. Am J Gastroenterol 2001; 96: 979-83.
81. Williams RBH, Maclean JC, Brake H, et al. Predictors of outcome in an open, therapeutic trial of omeprazole in patients with laryngitis. Gastroenterology 2002; 580: 122 (A580).